drugset / Trial / NCT00425100

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

NCT00425100

Phase 3 Completed 516 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.

Timeline

Start
2007-01
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg
Subject Fesoterodine Other / unclassified 8 mg

Indications